The program will be updated continuously with more information.
October 24 |
|
12.30 - 17.00 | |
11.30-12.30 | Lunch |
12.30-12.45 | Introduction by the Editor in chief at JIM Bo Angelin |
12.45 - 13.00 | Welcome Ulf Smith and James L. Kirkland |
Session 1 Contribution by cellular senescence and other mechanisms to metabolic dysfunction Chair: Tamara Tchkonia |
|
13.00-13.30 |
Age is not enough to identify increased CS in man Tamara Tchkonia, USA |
13.30 - 14.00 |
Developing new senolytic therapies - an update James L. Kirkland, USA |
14.00 - 14.30 |
Human pharmacokinetic and pharmacodynamic studies of senolytics: the case of fisetin Jan Nehlin, Denmark |
14.30 - 15.00 | Coffee |
15.00 - 15.30 |
Cell senescence in human metabolic cells and possibilities for senolytic therapy Ulf Smith, Sweden |
15.30 - 16.00 |
Targeting seno-anergy to treat age-related disease Tohru Minamino, Japan |
16.00 - 16.30 |
Functional rehabilitation of senescent pancreatic islets Cristina Aguayo-Mazzucato, USA |
16.30 - 17.00 |
Round table discussion Recorder: Rosa Spinelli |
October 25 |
|
08.30-17.00 | |
Session 2 Contribution of cellular senescence and other aging mechanisms to metabolic co- morbidities Chair: Thomas von Zglinicki |
|
08.30 - 09.00 |
Role of cell senescence in obesity Allyson K. Palmer, USA |
09.00 - 09.30 |
Adipocyte senescence in humans Kirsty Spalding, Sweden |
09.30 - 10.00 |
Role of cell senescence and senolytic therapy in NAFLD/NASH Stijn Meijnikman, Holland |
10.00 - 10.30 |
Metabolism as a targetable vulnerability of senescent cells Thomas von Zglinicki, UK |
10.30 - 11.00 | Coffee |
11.00 - 11.30 |
Round Table Discussion Recorder: Allyson Palmer |
Session 3 Senolytics as preventive agents and treatments for metabolic disease Chair: Nicolas Musi |
|
11.30 - 12.00 |
Gerotherapeutics for conditions associated with aging and the metabolic syndrome Iman Al-Naggar, USA |
12.00 - 12.30 |
Analysis of senescence in human adipose tissue using single nuclei Nicolas Musi, USA |
12.30 - 13.30 | Lunch |
Session 4 And for diabetic complications Chair: Nicolas Musi |
|
13.30 - 14.00 |
Targeting senescence in the diabetic heart Georgina Ellison, USA |
14.00 - 14.30 |
Diabetic eye complications Brittni Scruggs, USA |
14.30 - 15.30 | Coffee |
15.30 - 16.00 |
Unlocking the potential of topical senolytics for chronic diabetic wounds Saranya Wyles, USA |
16.00 - 16.30 |
Senolytic therapy for peripheral artery disease Mary M. McDermott, USA |
16.30 - 17.00 |
Round Table Discussion: Recorder: Saranya Wyles |
October 26 |
|
09.00 - 12.00 | |
Session 5 Novel prosenescent, senomorphic, and senolytic agents Chair: Barbara B. Kahn |
|
09.00 - 09.30 |
Hyperinsulinemia and new anti-diabetic agents target metabolic cell senescence Rosa Spinelli, Italy |
09.30 - 10.00 |
Novel signaling lipids which prevent and reverse pancreatic islet cell senescence Barbara B. Kahn, USA |
10.00 - 10.30 |
Senosensitizers - a novel class of agents James L. Kirkland, USA |
10.30 - 11.30 |
General discussion Lead by: James L. Kirkland and Ulf Smith. |
12.00 | Lunch and farewell |